Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Research & Development (2016 - 2025)

Sunshine Biopharma's Research & Development history spans 12 years, with the latest figure at $73501.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 50.76% year-over-year to $73501.0; the TTM value through Dec 2025 reached $604308.0, down 35.29%, while the annual FY2025 figure was $604308.0, 35.29% down from the prior year.
  • Research & Development reached $73501.0 in Q4 2025 per SBFM's latest filing, down from $119298.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $816328.0 in Q4 2023 to a low of $41763.0 in Q4 2022.
  • Average Research & Development over 5 years is $243905.4, with a median of $205754.5 recorded in 2025.
  • Peak YoY movement for Research & Development: skyrocketed 5177.66% in 2021, then plummeted 81.71% in 2024.
  • A 5-year view of Research & Development shows it stood at $91198.0 in 2021, then plummeted by 54.21% to $41763.0 in 2022, then surged by 1854.67% to $816328.0 in 2023, then tumbled by 81.71% to $149272.0 in 2024, then crashed by 50.76% to $73501.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Research & Development are $73501.0 (Q4 2025), $119298.0 (Q3 2025), and $196232.0 (Q2 2025).